Amendments To the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-7 (canceled)

8. (currently amended) The compound of Claim 23 wherein R^2 is selected from:

(1) -CH_2-(phenyl),
(2) -CH_2-(4-bromophenyl),
(3) -CH_2-(3-chlorophenyl),
(4) -CH_2-(3,5-difluorophenyl),
(5) -CH_2-((2-trifluoromethyl)phenyl),
(6) -CH_2-((3-trifluoromethyl)phenyl),
(7) -CH_2-((4-trifluoromethyl)phenyl),
(8) -CH_2-((3-trifluoromethoxy)phenyl),
~~(9) -CH_2-((3-trifluoromethylthio)phenyl),~~
~~(10) -CH_2-((3-trifluoromethoxy-5-thiomethyl)phenyl),~~
~~(11)~~ (9) -CH_2-((3-trifluoromethoxy-5-methoxy)phenyl),
~~(12) -CH_2-((3-trifluoromethoxy-5-methanesulfonyl)phenyl),~~
~~(13) -CH_2-((3-trifluoromethoxy-5-amino)phenyl),~~
~~(14) -CH_2-((3-trifluoromethoxy-5-aminomethanesulfonyl)phenyl),~~
~~(15) -CH_2-((3-trifluoromethoxy-5-sulfonylamino)phenyl),~~
~~(16)~~ (10) -CH_2-((3,5-bis-trifluoromethyl)phenyl),
~~(17)~~ (11) -CH_2-((3-fluoro-5-trifluoromethyl)phenyl),
~~(18)~~ (12) -$CH(CH_3)$-((3,5-bis-trifluoromethyl)phenyl), and
~~(19)~~ (13) -$C(CH_3)_2$-((3,5-bis-trifluoromethyl)phenyl)~~,~~.
~~(20) -CH_2-(4-(2-trifluoromethyl)pyridyl),~~
~~(21) -CH_2-(5-(3-trifluoromethyl)pyridyl),~~
~~(22) -CH_2-(5-(3-trifluoromethyl)pyridazinyl),~~
~~(23) -CH_2-(4-(2-trifluoromethyl)pyridyl-N-oxide), and~~
~~(24) -CH_2-(5-(3-trifluoromethyl)pyridyl-N-oxide).~~

9. (previously presented) The compound of Claim 23 wherein R^3 is heterocycle, where the heterocycle is selected from: imidazole, pyrimidyl, triazole and tetrazole,

where the heterocycle is unsubstituted or substituted with 1-5 substituents as defined in Claim 23.

10. (previously presented) The compound of Claim 23 wherein R^3 is heterocycle,

where the heterocycle is unsubstituted or substituted with 1-3 substituents independently selected from:

(a) halo,

(c) hydroxy,

(d) C_{1-3}alkyl,

(e) -O-C_{1-3}alkyl, and

(f) $-CO_2R^9$.

11. (previously presented) The compound of Claim 23 wherein R^3 is selected from: imidazole, pyrimidyl, triazole and tetrazole.

12. (previously presented) The compound of Claim 23 wherein R^3 is selected from:



Claims 13-17 (canceled)

18. (previously presented) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 23.

19. (withdrawn) A method for modulation of chemokine receptor activity in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim ~~1.~~ 23.

20. (withdrawn) A method for treating, ameliorating or controlling an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim ~~1.~~ 23.

21. (withdrawn) A method for reducing the risk of an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim ~~1.~~ 23.

22. (withdrawn) A method for treating, ameliorating or controlling rheumatoid arthritis which comprises administering to a patient in need thereof an effective amount of the compound of Claim ~~1.~~ 23.

23. (currently amended) A compound of the formula I:



I

wherein:

R^1 is selected from the group consisting of:

(1) -$CH(CH_3)_2$ and

(2) -$C(CH_3)_2(OH)$;

~~(1) CH_3,~~

~~(2) CH_2CH_3,~~

~~(3) $CH(CH_3)_2$,~~

~~(4) $CH_2CH_2CH_3$,~~

~~(5) $CH_2CH(CH_3)_2$,~~

~~(6) cyclopropyl,~~
~~(7) cyclobutyl,~~
~~(8) cyclopentyl,~~
~~(9) CH_2-cyclopropyl,~~
~~(10) CH_2-cyclobutyl,~~
~~(11) CH_2-cyclopentyl,~~
~~(12) CH_2OH,~~
~~(13) $C(CH_3)_2(OH)$,~~
~~(14) $C(CH_2OH)(CH_3)_2$,~~
~~(15) (OH)cyclobutyl,~~
~~(16) (OH)cyclopentyl,~~
~~(17) $C(CH_3)_2(NHCOCH_3)$,~~
~~(18) $C(CO_2H)(CH_3)_2$,~~
~~(19) O-CH_3,~~
~~(20) O-cyclopentyl,~~
~~(21) O-$CH(CH_3)_2$,~~
~~(22) S-CH_3,~~
~~(23) S-CF_3,~~
~~(24) SO_2-CH_3,~~
~~(25) S-$CH(CH_3)_2$,~~
~~(26) SO_2-$CH(CH_3)_2$, and~~
~~(27) NH-SO_2-CH_3;~~

R^2 is selected from the group consisting of -CH_2-phenyl, -$CH(CH_3)$-phenyl, and -$C(CH_3)_2$-phenyl, wherein phenyl is unsubstituted or substituted with 1-3 substituents independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) trifluoromethoxy,
(d) hydroxy,
(e) C_{1-3}alkyl,
(f) -O-C_{1-3}alkyl, and
(g) -CO_2H;
~~(g) CO_2-C_{1-3}alkyl,~~
~~(h) CO_2H,~~
~~(i) S-C_{1-3}alkyl,~~

~~(j) SO_2-C_{1-3}alkyl,~~
~~(k) SCF_3;~~
~~(l) NH_2;~~
~~(m) NH-SO_2-C_{1-3}alkyl, and~~
~~(n) SO_2-NH_2;~~

R^3 is a heterocycle, wherein the heterocycle is selected from the group consisting of benzoimidazolyl, ~~benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl,~~ imidazolyl, ~~indolinyl, indolyl, indolazinyl,~~ indazolyl, ~~isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxetanyl, pyranyl,~~ pyrazinyl, pyrazolyl, ~~pyridazinyl, pyridopyridinyl,~~ pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, ~~quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl,~~ tetrazolyl, ~~tetrazolopyridyl,~~ thiadiazolyl, thiazolyl, ~~thienyl,~~ triazolyl, and imidazolidinone; ~~azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl, and N-oxides thereof,~~

wherein the heterocycle is unsubstituted or substituted with 1-5 substituents independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -CN,
(h) -NR^9R^{10}, and
(i) -$CONR^9R^{10}$;

R^4, R^6, R^9 and R^{10} are H;

R^5 is selected from:

(a) hydrogen,
(b) $-CH_3$, and
(c) $-O-CH_3$; and

n is the integer 1; or

a pharmaceutically acceptable salt thereof or an individual diastereomer thereof.

24. (previously presented) The compound of Claim 23 which is selected from the group consisting of the compounds below, or a pharmaceutically acceptable salt or individual diastereomer thereof:

 Ex. 1	 Ex. 2
 Ex. 3	 and Ex. 64 .